New York, New York, United States QVT Financial appeared to be the VC, which was created in 2003. The venture was found in North America in United States. The main department of described VC is located in the New York.
The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the QVT Financial, startups are often financed by Sofinnova Partners, Gimv, Auriga Partners. The meaningful sponsors for the fund in investment in the same round are Venrock, Three Arch Partners, Foresite Capital. In the next rounds fund is usually obtained by Flagship Pioneering, Viking Global Investors, Three Arch Partners.
We also calculated 3 valuable employees in our database.
The average startup value when the investment from QVT Financial is more than 1 billion dollars. The high activity for fund was in 2014. The higher amount of exits for fund were in 2015. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 14 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this QVT Financial works on 40 percentage points more the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AveXis, Roivant Sciences, Adaptimmune. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Broadcasting, Content.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Clal Electronics Industries | - |
| Feiteng Chuangtou | China, Guangdong, Shenzhen |
| First Albany Companies | Albany, New York, United States |
| GKM | California, Los Angeles, United States |
| Mistral Equity Partners | New York, New York, United States |
| Northwest Venture Associates | Spokane, United States, Washington |
| RoseRock | Bryan, Texas, United States |
| ZOLL Medical Corporation | Chelmsford, Massachusetts, United States |
| Zuo'An Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Active Surfaces | $5M | 13 May 2024 | Salem, Massachusetts, United States | ||
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Tourmaline Bio | 01 May 2022 | New York, New York, United States | |||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States | ||
MP Materials | 01 Dec 2020 | Las Vegas, Nevada, United States | |||
Kriya Therapeutics | $80M | 12 May 2020 | Palo Alto, California, United States | ||
Adaptimmune | $104M | 25 Sep 2014 | United Kingdom, England, United Kingdom | ||
Concert Pharmaceuticals | $37M | 30 Apr 2008 | Massachusetts, United States | ||
Resolvyx Pharmaceuticals | $25M | 22 Apr 2008 | Cambridge, Massachusetts, United States |
– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Active Surfaces | $5M | 13 May 2024 | Salem, Massachusetts, United States | ||
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Tourmaline Bio | 01 May 2022 | New York, New York, United States | |||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States | ||
MP Materials | 01 Dec 2020 | Las Vegas, Nevada, United States | |||
Kriya Therapeutics | $80M | 12 May 2020 | Palo Alto, California, United States | ||
Adaptimmune | $104M | 25 Sep 2014 | United Kingdom, England, United Kingdom | ||
Concert Pharmaceuticals | $37M | 30 Apr 2008 | Massachusetts, United States | ||
Resolvyx Pharmaceuticals | $25M | 22 Apr 2008 | Cambridge, Massachusetts, United States |
